



Genetik och forskning

Anna Lindstrand (Docent & överläkare Klinisk Genetik)

Sällsynta dagen 4e mars 2020

KAROLINSKA University Hospital, Karolinska Institutet, gms

1

Sällsynta diagnoser
- Individuellt sällsynta men kollektivt viktiga!

RARE DISEASES by the NUMBERS	50% of the people affected by rare diseases are children	Approximately 7,000 rare diseases & disorders have been identified
30 MILLION PEOPLE in the U.S. are living with rare diseases	30 MILLION PEOPLE in Europe are living with rare diseases	#DYK: If all of the people with rare diseases lived in one country, it would be the world's 3rd most populous country


Source: Global Genes, <https://globalgenes.org/rare-diseases-facts-statistics/>

Definition på sällsynt diagnos: sjukdom som drabbar <5 per 10 000 personer*

2

~ 80% av sällsynta diagnoser har en genetisk bakgrund


Single gene conditions



Multifactorial conditions




Chromosomal conditions



Genomics Education Programme


3




4

Ökad förståelse för hur gener bidrar till hälsa och sjukdomar

- Upptäckt av gener för erkända Mendelska sjukdomar
- autosomt dominant, autosomt recessiv, X-bunden eller mitokondriell nedärvning
- Upptäckt av vanliga varianter vid vanliga sjukdomar
- Upptäckt av sällsynta varianter vid sällsynta och vanliga sjukdomar
- Drivs av ny genteknik med hög kapacitet




5



6


Lärdomar från studier av sällsynta sjukdomar



Posey, Orphanet Journal of Rare Diseases 2019


7

Nya tekniker innebär nya möjligheter



8

Precisionsmedicin



9


Efficient gene therapies are available – how do we find the patients?

Indication	Product	Regulatory approval	Market price*	Estimated number of eligible patients (US + Europe)
ADA-SCID ^b	Strimvelis (Orchard Therapeutics)	EMA-2016	€594,000	30–40
Leber amaurosis	Luxturna (Sparks Therapeutics)	FDA-2017/EMA-2018	\$850,000	>2,000
SMA ^c	Zolgensma (Novartis)	FDA-2019		
B-ALL ^d	Kymriah (Novartis)	FDA-2017/EMA-2018		
DLBCL ^e	Kymriah (Novartis)	FDA-2017/EMA-2018		
DLBCL ^f	Yescarta (Gilead)	FDA-2017/EMA-2018		
β-thalassemia ^g	Zynteglo (Bluebird)	EMA-2019		

019

10

Patient-Customized Oligonucleotide Therapy in Batten disease



Batten is a neurodegenerative disease which leaves children blind, cognitively impaired and bed-ridden before they die at a young age

Kim NEJM 2019; <https://www.stooebatten.org>

11

Forskargruppen Rare Diseases


- To solve the unsolved and phenotype the solved!



Extremt viktigt med

- 1) Teamwork
 - mellan kliniker, forskare, sjukhusgenetiker, bioinformatiker
- 2) Samarbete
 - Lokalt, nationellt och internationellt

Klinisk, radiologisk och beteendekarakterisering Next generation sequencing Funktionella studier Behandling



12

Vad händer i Stockholm?

Genomic Medicine Center Karolinska



Technology
Academic setting

+




Medical expertise
Healthcare


Joint unit for introduction of genomics technologies into clinical routine.
Focus areas on **rare diseases**, cancer and microbiology.
Covers a population of approximately 2.3 million in the Stockholm healthcare region




13



14



15



16

Vad vill vi uppnå med GMS


Genom en nationell kraftsamling kunna erbjuda alla patienter oavsett sjukvårdsregion:

- Den bästa diagnostiken – bl.a. med hjälp av de nya sekvenseringsteknologierna
- Precisionsmedicin – ge rätt behandling till rätt patient
- Unik nationell forskningsdatabas
- Innovation och företagssamverkan



Nationellt samarbete mellan samtliga sju regioner med universitetssjukvård, de 14 övriga regionerna, landets sju universitet med medicinsk fakultet, näringslivet samt patientorganisationer

17



18

Hum Mol Biol. 2018 Oct 30;19(10):1456-1467. doi: 10.1002/humu.23605. Epub 2018 Aug 22.

Alu-Alu mediated intragenic duplications in IFT81 and MATN3 are associated with skeletal dysplasias.

Patterson M¹, Vaz R², Hammarstedt A¹, Eidehell J^{2,3}, Carvalha CMB⁴, Hoffmeister W⁵, Thiem E¹, Hornumova E⁶, Voss L⁶, Nordin A¹, Nilsson G^{1,3}, Grigoriou G¹, Lindstrand A¹.

Maria Pettersson Raquel Vaz



Nat Med. 2019 Feb 25; doi: 10.1038/s41591-019-0352-2. [Epub ahead of print]


Gain-of-function mutation of microRNA-140 in human skeletal dysplasia.

Grigoriou G^{1,2,3}, Suzuki H⁴, Taitan E⁵, Mirzazadeh M⁶, Bonchewitz Z⁴, Aki G¹, Grigoriou G¹, Hammarstedt A^{1,3}, Mank E^{1,4}, Nordin A^{1,3}, Nordin A^{1,3}, Mank E^{1,4}, Extra DS

Giedre Grigorioune Fulya Tayan



25



26

KAROLINSKA University Hospital

Karolinska Institutet

gms



Anna.Lindstrand@ki.se

27